Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates

Advanced Drug Delivery Reviews

Volumn 56, Issue 8, 2004, Pages 1177-1192

  Gabizon, Alberto ^a   Shmeeda, Hilary ^b   Horowitz, Aviva T ^b   Zalipsky, Samuel ^b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Chemotherapy; Folate; Liposome; Murine tumor model; PEGylation; Targeting

Indexed keywords

AGENTS; CELLS; CHEMOTHERAPY; DRUG DOSAGE; LIPIDS; POLYETHYLENE GLYCOLS; TOXICITY; TUMORS;

CELLULAR COMPARTMENT; CHEMOTHERAPEUTIC AGENTS; FOLATE RECEPTOR (FR); LIPOSOME-ENTRAPPED DRUGS;

BIOMEDICAL ENGINEERING;

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; FOLATE RECEPTOR; FOLATE TARGETED LIPOSOME; FOLIC ACID; LIPOSOME; MACROGOL; MEMBRANE RECEPTOR; MITOPODOZIDE; NONTARGETED LIPOSOME; PHOSPHOLIPID; STEALTH; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BINDING AFFINITY; CARCINOMA CELL; CYTOTOXICITY; DRUG FORMULATION; HUMAN; INTRACELLULAR SPACE; LYMPHOMA CELL; MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR MODEL;

EID: 1942439013     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2004.01.011     Document Type: Article

References (39)

1. Lu Y., Low P.S. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv. Drug Deliv. Rev. 54:2002;675-693.
2. Lasic D.D., Martin F.J. Stealth Liposomes. 1995;CRC Press, Boca Raton.
3. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41:2001;189-207.
4. Gabizon A., Goren D., Horowitz A.T., Tzemach D., Lossos A., Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev. 24:1997;337-344.
5. Goren D., Horowitz A.T., Zalipsky S., Woodle M.C., Yarden Y., Gabizon A. Targeting of Stealth liposomes to erbB2 (Her/2) receptor: in vitro and in vivo studies. Br. J. Cancer. 74:1996;1749-1756.
6. Pan X.Q., Wang H., Lee R.J. Boron delivery to a murine lung carcinoma using folate receptor targeted liposomes. Anticancer Res. 22:2002;1629-1633.
7. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., Zalipsky S. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 9:2003;6551-6559.
8. Jain R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Release. 74:2001;7-25.
9. Gabizon A., Shmeeda H., Barenholz Y. Pharmacokinetics of PEGylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42:2003;419-436.
10. Reddy J.A., Low P.S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;587-627.
11. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
12. Rui Y., Wang S., Low P.S., Thompson D.H. Diplasmenylcholine-folate liposomes: an efficient vehicle for intra-cellular drug delivery. J. Am. Chem. Soc. 120:1998;11213-11218.
13. Turek J.J., Leamon C.P., Low P.S. Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J. Cell Sci. 106:1993;423-430.
14. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Mandelbaum-Shavit F., Qazen M.M., Zalipsky S. Targeting folate receptor with folate linked to extremities of poly(ethyleneglycol)-grafted liposomes: in vitro studies. Bioconjug. Chem. 10:1999;289-298.
15. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3318-3322.
16. Cabanes A., Tzemach D., Goren D., Horowitz A.T., Gabizon A. Comparative study of the anti-tumor activity of free doxorubicin and PEGylated liposomal doxorubicin in a mouse lymphoma model. Clin. Cancer Res. 4:1998;499-505.
17. Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA. 85:1988;6949-6953.
18. Gabizon A.A. Editorial: Stealth liposomes and tumor targeting: a step further in the quest for the magic bullet. Clin. Cancer Res. 7:2001;223-225.
19. Zalipsky S., Brandeis E., Newman M.S., Woodle M.C. Long circulating, cationic liposomes containing amino-PEG-phosphatidylethanolamine. FEBS Lett. 353:1994;71-74.
20. Lee R.J., Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
21. Goren D., Horowitz A.T., Tzemach D., Tarshish M., Zalipsky S., Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. 6:2000;1949-1957.
22. Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P., Leamon C.P. Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors. Gene Ther. 9:2002;1542-1550.
23. Kirpotin D., Hong K., Mullah N., Papahadjopoulos D., Zalipsky S. Liposomes with detachable polymer coating: destabilization and fusion of dioleoyl-phosphatidylethanolamine vesicles triggered by cleavage of surface-grafted poly(ethylene glycol). FEBS Lett. 388:1996;115-118.
24. Zalipsky S., Qazen M., Walker J.A., Mullah N., Quinn Y.P., Huang S.K. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacylphosphatidylethanolamine. Bioconjug. Chem. 10:1999;703-707.
25. Zalipsky S., Quinn Y., Jin B., Zhang W., Engbers C., Mullah N., Kiwan R., Huang S.K. New approach to gene delivery mediated by reversible PEGylation of cationic lipid-DNA complexes. Proc. Intl. Symp. Control. Rel. Bioact. Mater. 28:2001;1177-1178.
26. Zalipsky S., Mullah N., Harding J.A., Gittelman J., Guo L., DeFrees S.A. Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug. Chem. 8:1997;111-118.
27. Zalipsky S., Mullah N., Qazen M. Preparation of poly(ethylene glycol)-grafted liposomes with ligands at the extremities of the polymer chains. Duzgunes N. Liposomes. Methods Enzymol. 2004;. (in press).
28. Allen T.M., Sapra P., Moase E. Use of post-insertion method for the formation of ligand-coupled liposomes. Cell. Mol. Biol. Lett. 7:2002;889-894.
29. Gabizon A.A., Horowitz A.T., Tzemach D., Mak L., Zalipsky S., Abra R. Folate receptor targeting of PEGylated (STEALTH®) liposomal cisplatin enhances anti-tumor activity in mouse models without increasing toxicity. Proc. Am. Assoc. Cancer Res. 2002;. (Abstract # 2063).
30. Saul J.M., Annapragada A., Natarajan J.V., Bellamkonda R.V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control. Release. 92:2003;49-67.
31. Ni S., Stephenson S.M., Lee R.J. Folate receptor targeted delivery of liposomal daunorubiicn into tumor cells. Anticancer Res. 22:2002;2131-2135.
32. Gaber M.H. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia. J. Biochem. Mol. Biol. Bipophys. 6:2002;309-314.
33. Stephenson S.M., Yang W., Stevens P.J., Tjarks W., Barth R.F., Lee R.J. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res. 23:2003;3341-3345.
34. Pan X.Q., Wang H., Lee R.J. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm. Res. 20:2003;417-422.
35. Gabizon A.A. Liposomal anthracyclines. Hematol. Oncol. Clin. North Am. 8:1994;431-450.
36. Pan X.Q., Zheng X., Shi G., Wang H., Ratnam M., Lee R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-transretinoic acid. Blood. 100:2002;594-602.
37. Harrington K.J., Lewanski C.R., Northcote A.D., et al. Phase I-II study of PEGylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 12:2001;493-496.
38. Bandak S., Goren D., Horowitz A.T., Tzemach D., Gabizon A. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anti-Cancer Drugs. 10:1999;911-920.
39. Gabizon A., Huberty J., Straubinger R.M., Price D.C., Papahadjopoulos D. An improved method for in vivo tracing and imaging liposomes using a (67)gallium-deferoxamine complex. J. Liposome Res. 1:1988;123-135.